

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Paula Fernström et al.  
Serial No. : TBA  
Filed : May 2, 2006  
For : Imidazo[1,2-a]pyridine Derivatives for the Treatment of Silent Gastro-  
Esophageal Reflux  
Examiner : TBA  
Group Art Unit : TBA  
Docket No. : 1103326-0740

Express Mail Label: EV 500402878 US I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 in an envelope addressed to: Mail Stop PCT, Assistant Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450, on May 2, 2006.  <u>Bernard Mays</u> Name of person mailing paper or fee  <u>Bernard Mays</u> Signature of person mailing paper or fee
--

Mail Stop PCT  
Commissioner for Patents  
Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants submit this communication in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. Favorable consideration of the documents cited on the attached Form PTO/SB/08A is respectfully requested.

The referenced application is the U.S. national stage application of international application no. PCT/SE2004/001589, filed November 3, 2004 (the "PCT application"). The documents identified on the attached Form PTO/SB/08A include documents cited in the specification and/or the International Search Report ("ISR") which issued in connection with the

PCT application. Copies of the published PCT application, i.e., International Publication Number WO 2005/041961, and the ISR are included with this filing. The ISR is attached to and part of the published PCT application.

**Copies of Cited U.S. Patent Documents are Not Provided**

As announced in the Official Gazette of August 5, 2003, the requirement under 37 CFR 1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003 has been waived.

Accordingly, copies of the U.S. patents and/or published patent applications cited on the attached Form PTO/SB/08A are not provided with this Information Disclosure Statement.

**Time of Transmittal of Information Disclosure Statement**

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b)(2) concurrently with a new national stage patent application and, therefore, no fee should be due. However, if any fee is required, the Commissioner is authorized to charge such fee to Deposit Account No. 23-1703.

Dated: May 2, 2006

Respectfully submitted,

Andrew Fessak

Andrew Fessak  
Reg. No. 48,528

Customer No. 007470  
Direct Dial: (212) 819-8437